Hope mrs @Jojoe is well soon 🙂
Vaccine products for spring 2024 programme
It is not possible to predict which SARS-CoV-2 variants might be circulating in future months. For spring 2024, the latest monovalent Omicron vaccines are considered preferable; and mRNA Omicron XBB.1.5 COVID-19 variant vaccines that have been pre-procured as part of the UK’s pandemic emergency response are considered the most cost-effective vaccines for use under existing circumstances.
The following vaccines are advised for use in all individuals aged 18 years and over:
Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine. Dose: 30 micrograms
Moderna mRNA (Spikevax) XBB.1.5 vaccine. Dose: 50 micrograms
The following vaccines are advised for young people aged 12 to 17 years:
Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine. Dose: 30 micrograms
The following vaccines are advised for children aged 5 to 11 years:
Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine. Dose: 10 micrograms
The following vaccines are advised for children aged 6 months to 4 years:
Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine. Dose: 3 micrograms
Novavax Matrix-M adjuvanted COVID-19 vaccine (Nuvaxovid – latest authorised and available vaccine) may be used as a booster dose for persons aged 12 years and above when alternative products are considered not clinically suitable.
HIPRA bivalent COVID-19 vaccine (Bimervax) may be used as a booster dose for persons aged 16 years and above (reference 3) when alternative products are considered not clinically suitable.